P53 vaccines for the treatment of cancers
US8668905B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 12, 2006 |
| Grant date | Mar 11, 2014 |
| Priority date | — |
| Expiry date | Dec 14, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.